Why Savara Inc.’s (SVRA) Stock Is Down 5.59%
As of Thursday, August 13, Savara Inc.’s SVRA share price has dipped by 5.59%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.
Commentary & Analysis
Why Savara Inc.’s (SVRA) Stock Is Up 7.83%
As of Tuesday, July 21, Savara Inc.’s SVRA share price has surged by 7.83%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Savara Inc.’s (SVRA) Stock Is Down 5.47%
As of Monday, July 13, Savara Inc.’s SVRA share price has dipped by 5.47%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Savara Inc.’s (SVRA) Stock Is Up 5.49%
As of Wednesday, June 10, Savara Inc.’s SVRA share price has surged by 5.49%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Savara Inc.’s (SVRA) Stock Is Up 5.40%
As of Wednesday, May 20, Savara Inc.’s SVRA share price has surged by 5.40%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Financial Summary
| Share Statistics | SVRA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,364.7 | $282.4 | 48% |
|
| Shares Out (Mil) | 253.6 | 54.0 | 80% |
|
| Institutional Ownership | 96.5% | 93.1% | 70% |
|
| Float (Mil) | 129.7 | 42.2 | 66% |
|
| Beta | 0.26 | 0.94 | 16% |
|
| Avg Daily Volume (000s) | 1,348 | 482 | 77% |
|
| Price Change (52-week) |
50.0% | 59.9% | 81% |
|
| Growth | SVRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (19.1%) | (10.1%) | 21% |
|
| EPS (5yr) | 8.2% | 15.9% | 44 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 16.9% | (15.6%) | 76% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 5 | 5 | 5 | |
| Current EPS | ($0.156) | ($0.616) | ($0.312) | |
| Month Ago EPS | ($0.148) | ($0.580) | ($0.294) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 1 | 0 | 1 | |
| Three Months Ago EPS | ($0.148) | ($0.580) | ($0.294) | |
| Year/Year Chg | (1.9%) | 15.4% | (136.1%) | |
| Financials | SVRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($139) | ($43) | 9% |
|
| EPS (TTM) | ($0.578) | ($1.500) | 26% |
|
| Operating Cash Flow (TTM) (Mil) | ($110) | ($31) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $24 | $2 | 64% |
|
| Long-Term Debt (Q1) (Mil) | $30 | $4 | 35% |
|
| Enterprise Value (Q1) (Mil) | $1,304 | $190 | 43% |
|
| Valuation | SVRA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 9.42 | 2.84 | 89% |
|
| P/E | na | 20.2 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | SVRA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (78.3%) | (47.7%) | 7% |
|
| ROE | (105.5%) | (55.0%) | 9% |
|
| Liabilities to Assets | 25.2% | 29.8% | 17% |
|
| F-Score | 2 | 3 | 7% |
|
Savara Inc. did not pass any screens on 9/4/2026.
